The 2026 Acute Pulmonary Embolism Guidelines were recently released. They recommend low-molecular-weight heparin (LMWH) over heparin for hospitalized patients with acute PE who require initial parenteral therapy unless they are in Category E2 Acute PE Cardiopulmonary Failure (level 1B-R).
Top benefits include:
- Reduce recurrent VTE
- Reduce bleeding
- More predictable response